Natural history of longitudinally extensive transverse myelitis in 35 Hispanic patients with systemic lupus erythematosus: good short-term functional outcome and paradoxical increase in long-term mortality

Background and objective Acute transverse myelitis (TM) is an infrequent neurological complication of systemic lupus erythematosus (SLE). Short-term outcome varies widely between cohorts. Little is known about the epidemiology and long-term functional outcome of TM associated to SLE. Methods Patients with SLE and acute TM were identified during hospital admission, visits to the Emergency Room or the Neurology Outpatient Clinic. We evaluated ambispectively those patients with SLE presenting with clinical myelopathy and corroborated with spinal MRI. Cases were divided as partial (non-paralyzing) or complete (paralyzing). We determined long-term functional outcome as well as mortality in those patients with follow-up periods of at least five years. Results We identified 35 patients (partial, n = 15; complete, n = 20) in which complete clinical and imaging data were available (26 with follow-up ≥ 5 years). Patients with complete TM were significantly older than those with partial forms. Positive antiphospholipid antibodies were observed in 80% of patients, suggesting a possible mechanistical role. Surprisingly, functional recovery at one year was in general good; however, we observed a five-year mortality of 31% because of sepsis (in 10 cases) or pulmonary embolism (in one case). Conclusions Short-term outcome of SLE-related TM is generally good, and recurrence rate is low. However, we observed a long-term fatality rate of 31% for reasons unrelated to TM, suggesting that TM is a manifestation of severe immune dysregulation and a predictor of severity and mortality in patients with SLE.

[1]  L. Llorente,et al.  Myelitis in systemic lupus erythematosus: clinical characteristics and effect in accrual damage. A single-center experience , 2017, Lupus.

[2]  C. Tan International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2016, Neurology.

[3]  R. Sankowski,et al.  Systemic Inflammation and the Brain: Novel Roles of Genetic, Molecular, and Environmental Cues as Drivers of Neurodegeneration , 2015, Front. Cell. Neurosci..

[4]  T. Frohman,et al.  Transverse Myelitis , 2012, Neurologic Clinics.

[5]  B. Weinshenker,et al.  Evidence-based guideline: Clinical evaluation and treatment of transverse myelitis: [RETIRED] , 2011, Neurology.

[6]  Gerald McGwin,et al.  Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. , 2012, Arthritis and rheumatism.

[7]  J. D. de Carvalho,et al.  Clinical, radiologic, and therapeutic analysis of 14 patients with transverse myelitis associated with antiphospholipid syndrome: report of 4 cases and review of the literature. , 2011, Seminars in arthritis and rheumatism.

[8]  M. Gershwin,et al.  The epidemiology of transverse myelitis. , 2010, Autoimmunity reviews.

[9]  G. Espinosa,et al.  Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. , 2010, Seminars in arthritis and rheumatism.

[10]  I. Izbudak,et al.  Distinct subtypes of myelitis in systemic lupus erythematosus. , 2009, Arthritis and rheumatism.

[11]  S. Ye,et al.  Prognostic factors of lupus myelopathy , 2008, Lupus.

[12]  S. Valdés-Ferrer,et al.  Cerebral Changes in SLE With or Without Antiphospholipid Syndrome. A Case‐Control MRI Study , 2008, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[13]  L. Pasquier,et al.  Orphanet Journal of Rare Diseases , 2006 .

[14]  S. Vukusic,et al.  Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis , 2006, Annals of neurology.

[15]  Ichiro Nakashima,et al.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis , 2004, The Lancet.

[16]  J. Allanson,et al.  Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. , 2004, The Journal of rheumatology.

[17]  A. Amoroso,et al.  Neuropsychiatric lupus syndromes , 2003, Neurology.

[18]  L. Morrison,et al.  Proposed diagnostic criteria and nosology of acute transverse myelitis , 2003 .

[19]  Y. Shoenfeld,et al.  Transverse Myelitis in Patients with Antiphospholipid Antibodies – The Importance of Early Diagnosis and Treatment , 2002, Clinical Rheumatology.

[20]  G. Gronseth,et al.  Neuropsychiatric syndromes in lupus: Prevalence using standardized definitions , 2002, Neurology.

[21]  J. Piette,et al.  Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. , 2002, Arthritis and rheumatism.

[22]  J. Téllez-Zenteno,et al.  Longitudinal myelitis associated with systemic lupus erythematosus: clinical features and magnetic resonance imaging of six cases , 2001, Lupus.

[23]  J. Peltola,et al.  The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus , 2001, Neurology.

[24]  A. Hernández,et al.  Mielitis transversa en el lupus eritematoso sistémico , 2000 .

[25]  R. DeHoratius,et al.  Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature , 2000, Annals of the rheumatic diseases.

[26]  W A Wilson,et al.  International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. , 1999, Arthritis and rheumatism.

[27]  C. Lau,et al.  Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment, and outcome. , 1998, The Journal of rheumatology.

[28]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[29]  D. Alarcón-Segovia,et al.  Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. , 1992, Seminars in arthritis and rheumatism.

[30]  J. Sánchez-Guerrero,et al.  Antiphospholipid Antibodies and the Antiphospholipid Syndrome in Systemic Lupus Erythematosus A Prospective Analysis of 500 Consecutive Patients , 1989, Medicine.

[31]  A. Rowan,et al.  Myelopathy in systemic lupus erythematosus. , 1968, Archives of neurology.

[32]  Faan,et al.  Academy of transverse myelitis : Report of the Therapeutics and Technology Evidence-based guideline : Clinical evaluation and treatment of December 16 , 2011 .

[33]  Patrick Vermersch,et al.  Neuromyelitis optica and non organ-specific autoimmunity. , 2008, Archives of neurology.

[34]  Chan Jun-mi,et al.  International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome(APS) , 2008 .